Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocin‐induced type 1 diabetes
暂无分享,去创建一个
John D Imig | J. Imig | Ahmed A Elmarakby | Jessica Faulkner | Mohammed Al-Shabrawey | Mong-Heng Wang | Krishna Rao Maddipati | M. Wang | Jessica L. Faulkner | Ahmed A. Elmarakby | M. Al–Shabrawey
[1] S. Imaoka,et al. Regulation of soluble epoxide hydrolase (sEH) in mice with diabetes: high glucose suppresses sEH expression. , 2009, Drug metabolism and pharmacokinetics.
[2] B. Hammock,et al. Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain. , 2006, Life sciences.
[3] J. Lawler,et al. Thrombospondin-1 Is an Endogenous Activator of TGF-β in Experimental Diabetic Nephropathy In Vivo , 2007, Diabetes.
[4] R. Atkins,et al. Macrophage accumulation in human progressive diabetic nephropathy , 2006, Nephrology.
[5] B. Hammock,et al. Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. , 2009, American journal of physiology. Renal physiology.
[6] N. Abraham,et al. Heme oxygenase: the key to renal function regulation. , 2009, American journal of physiology. Renal physiology.
[7] R. Atkins,et al. Macrophages in streptozotocin-induced diabetic nephropathy: potential role in renal fibrosis. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[8] P. Pratt,et al. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. , 1996, Circulation research.
[9] J. Pollock,et al. Distinct Actions of Endothelin A-Selective Versus Combined Endothelin A/B Receptor Antagonists in Early Diabetic Kidney Disease , 2011, Journal of Pharmacology and Experimental Therapeutics.
[10] J. Falck,et al. Role of Soluble Epoxide Hydrolase in Postischemic Recovery of Heart Contractile Function , 2006, Circulation research.
[11] Maristela L Onozato,et al. Suppressing renal NADPH oxidase to treat diabetic nephropathy , 2007, Expert opinion on therapeutic targets.
[12] K. Ley,et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. , 1999, Science.
[13] M. Clare-Salzler,et al. Eicosanoid Imbalance in the NOD Mouse Is Related to a Dysregulation in Soluble Epoxide Hydrolase and 15‐PGDH Expression , 2005, Annals of the New York Academy of Sciences.
[14] Sampathkumar Anandan,et al. Pharmacokinetics and Pharmacodynamics of AR9281, an Inhibitor of Soluble Epoxide Hydrolase, in Single‐ and Multiple‐Dose Studies in Healthy Human Subjects , 2012, Journal of clinical pharmacology.
[15] Sun Young Park,et al. Increased Expression and Activity of 12-Lipoxygenase in Oxygen-Induced Ischemic Retinopathy and Proliferative Diabetic Retinopathy , 2011, Diabetes.
[16] J. Shyy,et al. The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[17] D. Zeldin,et al. Increased CYP2J3 Expression Reduces Insulin Resistance in Fructose-Treated Rats and db/db Mice , 2010, Diabetes.
[18] M. Wellner,et al. A peroxisome proliferator-activated receptor-alpha activator induces renal CYP2C23 activity and protects from angiotensin II-induced renal injury. , 2004, The American journal of pathology.
[19] H. Krum,et al. Tranilast attenuates diastolic dysfunction and structural injury in experimental diabetic cardiomyopathy. , 2007, American journal of physiology. Heart and circulatory physiology.
[20] S. Chakrabarti,et al. Diabetes-induced Activation of Nuclear Transcriptional Factor in the Retina, and its Inhibition by Antioxidants , 2003, Free radical research.
[21] Y. Jeon,et al. Involvement of NF-κB in High Glucose-induced Alteration of a-methyl-D-glucopyranoside (α-MG) Uptake in Renal Proximal Tubule Cells , 2003, Cellular Physiology and Biochemistry.
[22] E. Inscho,et al. Chemokine Receptor 2b Inhibition Provides Renal Protection in Angiotensin II–Salt Hypertension , 2007, Hypertension.
[23] John V Pearson,et al. Identification of PVT1 as a Candidate Gene for End-Stage Renal Disease in Type 2 Diabetes Using a Pooling-Based Genome-Wide Single Nucleotide Polymorphism Association Study , 2007, Diabetes.
[24] S. Ledbetter,et al. Transforming Growth Factor-&bgr;, 20-HETE Interaction, and Glomerular Injury in Dahl Salt-Sensitive Rats , 2005 .
[25] S. Hwang,et al. Inhibition or Deletion of Soluble Epoxide Hydrolase Prevents Hyperglycemia, Promotes Insulin Secretion, and Reduces Islet Apoptosis , 2010, Journal of Pharmacology and Experimental Therapeutics.
[26] J. Imig. Targeting Epoxides for Organ Damage in Hypertension , 2010, Journal of cardiovascular pharmacology.
[27] B. Kestenbaum,et al. Central obesity, incident microalbuminuria, and change in creatinine clearance in the epidemiology of diabetes interventions and complications study. , 2007, Journal of the American Society of Nephrology : JASN.
[28] N. Abraham,et al. Heme oxygenase: a target gene for anti-diabetic and obesity. , 2008, Current pharmaceutical design.
[29] B. Hammock,et al. Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats. , 2009, Clinical science.
[30] K. Tomer,et al. Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension‐induced renal injury in mice , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[31] B. Hammock,et al. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors , 2006, Proceedings of the National Academy of Sciences.
[32] E. Inscho,et al. Glomerular 20-HETE, EETs, and TGF-beta1 in diabetic nephropathy. , 2009, American journal of physiology. Renal physiology.
[33] N. Abraham,et al. Heme oxygenase-1 prevents superoxide anion-associated endothelial cell sloughing in diabetic rats. , 2004, Biochemical and biophysical research communications.
[34] S. Ledbetter,et al. Transforming Growth Factor-, 20-HETE Interaction , and Glomerular Injury in Dahl Salt-Sensitive Rats , 2005 .
[35] D. Heudes,et al. Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. , 2000, Diabetes.
[36] K. Ley,et al. Leukocyte recruitment and vascular injury in diabetic nephropathy. , 2006, Journal of the American Society of Nephrology : JASN.
[37] W. Brown,et al. Microvascular complications of diabetes mellitus: renal protection accompanies cardiovascular protection. , 2008, The American journal of cardiology.
[38] J. Imig,et al. Tumor Necrosis Factor α Blockade Increases Renal Cyp2c23 Expression and Slows the Progression of Renal Damage in Salt-Sensitive Hypertension , 2006 .
[39] J. Pollock,et al. TNF-α inhibition reduces renal injury in DOCA-salt hypertensive rats , 2008 .
[40] J. Pollock,et al. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. , 2004, Journal of the American Society of Nephrology : JASN.
[41] H. Makino,et al. Role of macrophages in the pathogenesis of diabetic nephropathy. , 2001, Contributions to nephrology.
[42] F. Gonzalez,et al. Targeted Disruption of Soluble Epoxide Hydrolase Reveals a Role in Blood Pressure Regulation* , 2000, The Journal of Biological Chemistry.
[43] K. Sharma,et al. Regulation of transforming growth factor beta in diabetic nephropathy: implications for treatment. , 2007, Seminars in nephrology.
[44] J. Imig,et al. Tumor necrosis factor alpha blockade increases renal Cyp2c23 expression and slows the progression of renal damage in salt-sensitive hypertension. , 2006, Hypertension.
[45] Trevor A. Mori,et al. Induction of Heme Oxygenase-1 In Vivo Suppresses NADPH Oxidase–Derived Oxidative Stress , 2007, Hypertension.
[46] B. Hammock,et al. An Orally Active Epoxide Hydrolase Inhibitor Lowers Blood Pressure and Provides Renal Protection in Salt-Sensitive Hypertension , 2005, Hypertension.
[47] S. Ryter,et al. Carbon Monoxide Protects against Hyperoxia-induced Endothelial Cell Apoptosis by Inhibiting Reactive Oxygen Species Formation* , 2007, Journal of Biological Chemistry.
[48] J. Imig,et al. Obesity is the major contributor to vascular dysfunction and inflammation in high-fat diet hypertensive rats. , 2009, Clinical science.
[49] R. Elston,et al. Examination of association with candidate genes for diabetic nephropathy in a Mexican American population. , 2010, Clinical journal of the American Society of Nephrology : CJASN.
[50] N. Abraham,et al. Rat mesenteric arterial dilator response to 11,12-epoxyeicosatrienoic acid is mediated by activating heme oxygenase. , 2006, American journal of physiology. Heart and circulatory physiology.
[51] R. Stocker,et al. Pharmacologic induction of heme oxygenase-1. , 2007, Antioxidants & redox signaling.
[52] J. Falck,et al. 11,12-epoxyeicosatrienoic acid stimulates heme-oxygenase-1 in endothelial cells. , 2007, Prostaglandins & other lipid mediators.
[53] J. Navarro-González,et al. Pathogenic perspectives for the role of inflammation in diabetic nephropathy. , 2009, Clinical science.
[54] J. Falck,et al. Epoxyeicosatrienoic Acid Agonist Rescues the Metabolic Syndrome Phenotype of HO-2-Null Mice , 2009, Journal of Pharmacology and Experimental Therapeutics.
[55] R. Roman,et al. Role of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids in hypertension , 2004, Current opinion in nephrology and hypertension.
[56] Paul D. Jones,et al. Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation , 2009, British journal of pharmacology.
[57] C. Wilcox,et al. NADPH oxidases in the kidney. , 2006, Antioxidants & redox signaling.
[58] J. Pollock,et al. Endothelin Mediates Superoxide Production and Vasoconstriction through Activation of NADPH Oxidase and Uncoupled Nitric-Oxide Synthase in the Rat Aorta , 2005, Journal of Pharmacology and Experimental Therapeutics.